Nov 18, 2019
Medicenna to Host a Key Opinion Leader Symposium on MDNA55 for Treatment of Recurrent Glioblastoma
Nov 14, 2019
Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neuro-Oncology
Nov 14, 2019
EMulate® Therapeutics Announces Multiple Presentations on the Voyager and Hælo® systems
Nov 12, 2019
AIVITA Biomedical Announces New Positive Phase 2 Glioblastoma Data at SITC Annual Meeting Podium Presentation
Nov 11, 2019
DNAtrix to Present Updated Results from the Phase 2 CAPTIVE / KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
Nov 08, 2019
Brain Cancer Patient Survival, Immune and Tumor Data from AIVITA Biomedical's Phase 2 Clinical Trial to be Presented at SITC Annual Meeting
Nov 05, 2019
DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083
Nov 01, 2019
AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November
Oct 22, 2019
BERG Collaboration Identifies Novel Mechanism Of Action Of Redox Regulation By BPM 31510 In Models Of Glioblastoma
Oct 15, 2019
Denovo Biopharma Receives FDA's Permission to Proceed with a Biomarker-Guided Phase 2b Clinical Trial with DB102 (Enzastaurin) In First-Line Treatment of Glioblastoma (GBM)
Sep 25, 2019
Medicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress
Sep 13, 2019
Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
Sep 12, 2019
Medicenna to Present Latest Data from the MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress
Aug 28, 2019
EMulate Therapeutics® Submits Application for CE Mark
Aug 14, 2019
Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trial
Aug 14, 2019
Henry Ford Cancer Institute Enrolls First Patient in World's Largest Brain Cancer Clinical Trial
Aug 14, 2019
photonamic GmbH & Co. KG (Germany) Acquires the Oncology Business from MolecuLight Inc. (Canada)
Aug 13, 2019
KIYATEC Announces Addition of Capital Health as Clinical Site in Trial to Predict GBM Patient-Specific Response to Cancer Drugs Prior to Treatment
Aug 13, 2019
DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
Aug 06, 2019
Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models